Nabil Saba, MD

Director of Head & Neck Oncology, Vice Chair at @WinshipAtEmory. Medical Oncologist; H&N cancer expert. Opinions=my own

[NRG Oncology @NRGonc]

NRG Oncology research presented at #ASCO26 starts today with two #HeadandNeckCancer trials highlighted during poster sessions. Check out ↪️NRG-HN006 with Dr. Stephen Lai and NRG-HN015 with @DrNabilSaba

[Med-IQ @MedIQCME]

Join @DrHaddadRobert and @DrNabilSaba on Friday, March 6th @ 12 pm ET for a discussion of the latest clinical study data on novel therapies for R/M HNSCC, with emphasis on trial results presented at #MHNCS26. https://t.co/tksmDA2iTo

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 phase II trial of the trop-2 / Topo 1 ADC, Sacituzumab Govitecan in recurrent post PD1 metastatic #HNSCC presented as a TIP #MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 encouraging results of NBTXR3 with SBRT in recurrent post PD1 failure R/M #HNSCC with ORR exceeding 60% in this early data #MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS 26 FORTIFI HN01 A pivotal phase III trial examining Ficerafusp Alfa + Pembro vs Pembro in HPV unrelated #HNSCC, TIP presentation #MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 AHEAD MERIT pivotal phase II / III trial of HPV 16 E6,E7 mRNA immunotherapy : BNT 113 + Pembro vs Pembro in RM PDL1 + HPV 16 #HNSCC, TIP #MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 Ficlatuzumab + Cetuximab vs Cetuximab for second line RM # HNSCC, pivotal phase III trial relying on overcoming EGFR resistance through targeting met, FIERCE HN trial, #MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 updates from KN689 as to surgical data; EFS correlates with mPR; surgical rate is similar in both arms, #MedIQMHNCS26 #HNSCC

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 predictive and prognostic IO markers to be analyzed for R/M #HNSCC in the Phoenix tissue procurement study, so far 52 patients enrolled; a TIP poster session #MedIQMHNCS26

[Med-IQ @MedIQCME]

#MHNCS26 starts tomorrow! Don't miss @DrNabilSaba posting live updates on advances in R/M #HNSCC treatment from the meeting.
#MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 ongoing Evolve trial is a global study of Volrustamab vs observation post definitive Chemo RT in LA #HNSCC updated in a TIP poster session #MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 preoperative SC Amivantamab shows tolerability and encouraging responses with ORR of 46% in this cohort of pre and post Ami + Pembro resectable HPV - #HNSCC #MedIQMHNCS26

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 the only STAT3 targeted ASO shows no increase in response compared to single agent Pembro in 1st line randomized PEMDA Denvatirsen Pembro vs Pembro phase II study #MedIQMHNCS26 #HNSCC

[Nabil Saba, MD @DrNabilSaba]

#MHNCS26 encouraging responses with Ficerafusp Alfa 2000 mg Q 2 weeks and Pembro 400 Q 6 in 1st line RM HPV - HNSCC , ORR 48% CR 26% #MedIQMHNCS26 #HNSCC

[Nabil Saba, MD @DrNabilSaba]

Encouraging results with ORR 56% CR 10% shrinkage of tumor in 82% in Origami 4 Amivantamab + Pembro cohort #MHNCS26
#MedIQMHNCS26 #HNSCC

[David J. Lee, MD @djlee714]

Thank you to @DrNabilSaba for taking the time to chat with @AlexisNarvaezMD and myself regarding @NRGonc-HN015: Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head & Neck Cancer (NEOPOLIS). Stay tuned for the full interview soon!

[NRG Oncology @NRGonc]

Study Activation! NRG-HN015 A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)
@DrNabilSaba
https://t.co/0xIh7Rz38N

[Nabil Saba, MD @DrNabilSaba]

BNT113 Granted Fast Track Designation in HPV16-Positive HNSCC | CancerNetwork ⁦@BioNTech_Group⁩ ⁦@WinshipAtEmory⁩ #HPV https://t.co/GyVER9md5L

[ACS Journal Cancer @JournalCancer]

New editorial by Jose A. Monteiro MD, Yong Teng PhD, @NikkiSchmittMD, and @DrNabilSaba | Integrating systemic therapy into larynx preservation: Lessons from 3 decades of progress

https://t.co/TO57HKIY7w

@OncoAlert

[Alexis R. Narvaez-Rojas, M.D. (DrN) @AlexisNarvaezMD]

Full @RTOGFoundation @NRGOncology #radonc #update on Head &Neck #Particle therapy #trials: NRG-HN009 Dr Paul Harari, HN014 @DrNeilGross @UWCarbone , HN015 @DrNabilSaba @WinshipAtEmory and CC013 Dr David Brizel @DukeCancer provided by Dr @AnnaLeeMDMPH @MDAndersonNews